Author

A. Tulpule

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Assay:clinical cohort / trial· 1

Frequent Co-Authors

T. G. Bivona· 3 shared A. Heslin· 2 shared B. Huang· 2 shared J. Guan· 2 shared s. perati· 2 shared Y. P. Lin· 2 shared A. D. Ramirez· 1 shared A. J. Sabnis· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

T. G. Bivona

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

FET fusion oncoproteins disrupt physiologic DNA repair and create a targetable opportunity for ATR inhibitor therapy

S. Menon, D. Gracilla, M. R. Breese, Y. P. Lin, F. S. Dela Cruz, T. Feinberg, E. De Stanchina, A.-F. Galic, H. Allegakoen, s. perati, N. Wen, A. Heslin, M. Horlbeck, J. S. Weissman, A. Sweet-Cordero, , A. Tulpule

This study shows FET fusion oncoproteins disrupt DNA repair by inhibiting ATM signaling, making ATR inhibitors a potential therapy for FET rearranged cancers.

bioRxiv · Apr 30, 2023 · PreprintCancer Biology

Oncogenic protein condensates suppress growth factor perception and modulate drug tolerance

D. Gonzalez-Martinez, L. Roth, T. Mumford, J. Guan, B. Huang, A. Tulpule, T. G. Bivona, L. J. Bugaj

This study shows that oncogenic protein condensates suppress RTK signaling and modulate drug tolerance in ALK-driven cancers by sequestering adapter proteins and enabling paracrine survival signals.

bioRxiv · Feb 2, 2022Cancer Biology

Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules

A. Tulpule, J. Guan, D. S. Neel, Y. P. Lin, A. Heslin, H. R. Allegakoan, S. Perati, A. D. Ramirez, X. Shi, B. Yang, S. Feng, S. Makhija, D. Brown, B. Huang, T. G. Bivona

This study identifies membraneless protein granules formed by RTK oncoproteins that activate RAS/MAPK signaling independently of lipid membranes in cancer.

bioRxiv · Apr 9, 2020Cancer Biology

Synthetic essentiality of metabolic regulator PDHK1 in PTEN-deficient cells and cancers

N. Chatterjee, E. Pazarentzos, G. Hrustanovic, L. Lin, E. Verschueren, J. R. Johnson, M. Hofree, J. J. Yan, V. Olivas, B. W. Newton, J. V. Dollen, C. H. Earnshaw, J. Flanagan, E. Chan, S. Asthana, , T. G. Bivona

The paper identifies PDHK1 as a synthetic-essential gene in PTEN-deficient cells and cancers, showing its upregulation drives aerobic glycolysis and correlates with poor patient survival.

bioRxiv · Oct 11, 2018Cancer Biology